Company Description
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
The company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations.
It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H.
Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria.
In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19.
The company was incorporated in 1971 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1971 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Zackary Irani |
Contact Details
Address: 17571 Von Karman Avenue Irvine, California 92614 United States | |
| Phone | (949) 645-2111 |
| Website | biomerica.com |
Stock Details
| Ticker Symbol | BMRA |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0000073290 |
| CUSIP Number | 09061H307 |
| ISIN Number | US09061H3075 |
| Employer ID | 95-2645573 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Zackary S. Irani | Chief Executive Officer and Director |
| Allen C. Barbieri | Executive Vice-Chairman of the Board and Corporate Secretary |
| Gary Lu CPA | Principal Accounting Officer and Chief Financial Officer |
| Lucy Liu Ph.D. | Director of Manufacturing and Technical Operations |
| Robert W. Carlson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 10-Q | Quarterly Report |
| Sep 30, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 28, 2024 | 10-K | Annual Report |
| Jun 28, 2024 | 8-K | Current Report |
| May 10, 2024 | 424B5 | Filing |
| May 10, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 10-Q | Quarterly Report |